In the wake of the increase in Current Liabilities in the third quarter 2019, Quick Ratio fell to 6.07 a new company low.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Avedro Inc in third quarter 2019. While Quick Ratio total ranking has improved so far during the Q3 2019 to 533, from total ranking in the second quarter 2019 at 543.

Explain Quick Ratio?
How much Cash & cash equivalents AVDR�s has?
What are AVDR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AVDR Quick Ratio	(Sep 30 2019) Q3	(Jun 30 2019) Q2	(Mar 31 2019) Q1	(Dec 31 2018) Q3	Q2
Y / Y Current Liabilities Change	-	-	-	-	-
Y / Y Cash & cash equivalent Change	-	-	-	-	-
Quick Ratio MRQ	6.07	7.47	7.46	1.94	-
AVDR's Total Ranking	# 533	# 543	# 539	#	#
Seq. Current Liabilities Change	10.87 %	-10.79 %	72.4 %	-	-
Seq. Cash & cash equivalent Change	-9.84 %	-10.76 %	563.41 %	-	-

Quick Ratio third quarter 2019 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 186
Healthcare Sector	# 278
Overall Market	# 533

Quick Ratio Statistics
High	Average	Low
7.47	7	6.07
(Jun 30 2019)		(Sep 30 2019)

Financial Statements
Avedro Inc's Current Liabilities	$ 9 Millions	Visit AVDR's Balance sheet
Avedro Inc's Cash & cash equivalent	$ 52 Millions	Visit AVDR's Balance sheet
Source of AVDR's Sales		Visit AVDR's Sales by Geography

Cumulative Avedro Inc's Quick Ratio

AVDR's Quick Ratio for the trailling 12 Months

AVDR Quick Ratio	(Sep 30 2019) 12 Months	(Jun 30 2019) 12 Months	(Mar 31 2019) 12 Months	(Dec 31 2018) 12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	-	-	-	-	-
Quick Ratio TTM	6.14	6.17	5.44	1.94	-
Total Ranking TTM	# 394	# 0	# 0	#
Seq. Current Liabilities TTM Growth	40.01 %	56.46 %	172.4 %	-	-
Seq. Cash & cash equivalent TTM Growth	39.38 %	77.55 %	663.41 %	-	-

Quick ratio ranking by company, industry and sector >> Back to AVDR Financial Strength Comparisons >> Go to Compare AVDR Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2019 to $8.59 millions, cumulative Quick Ratio decreased to 6.14 below the Avedro Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Avedro Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 0 to 394.

Explain Quick Ratio?
How much Cash & cash equivalents AVDR�s has?
What are AVDR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 186
Healthcare Sector	# 278
Within the Market	# 394

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.47	7	6.07
(Jun 30 2019)		(Sep 30 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2019 MRQ Cash & cash equivalent	Sep 30 2019 MRQ Current Liabilities
Dianthus Therapeutics Inc	16.68	$ 160.570 Millions	$ 9.629 Millions
Verrica Pharmaceuticals Inc	16.42	$ 71.078 Millions	$ 4.330 Millions
Crescent Biopharma Inc	16.38	$ 170.939 Millions	$ 10.436 Millions
Marker Therapeutics inc	16.23	$ 48.500 Millions	$ 2.988 Millions
Kezar Life Sciences Inc	16.00	$ 85.243 Millions	$ 5.327 Millions
Milestone Pharmaceuticals Inc	15.45	$ 136.501 Millions	$ 8.836 Millions
Matinas Biopharma Holdings Inc	15.20	$ 32.665 Millions	$ 2.149 Millions
Deciphera Pharmaceuticals Inc	15.17	$ 634.595 Millions	$ 41.841 Millions
Global Blood Therapeutics Inc.	14.64	$ 603.104 Millions	$ 41.193 Millions
Equillium Inc	14.56	$ 62.238 Millions	$ 4.274 Millions
Boundless Bio Inc	14.37	$ 351.464 Millions	$ 24.455 Millions
Cnbx Pharmaceuticals Inc	14.30	$ 6.277 Millions	$ 0.439 Millions
Anaptysbio Inc	14.16	$ 421.002 Millions	$ 29.730 Millions
G1 Therapeutics Inc	14.13	$ 299.933 Millions	$ 21.222 Millions
Enanta Pharmaceuticals Inc	13.82	$ 335.236 Millions	$ 24.259 Millions
Ngm Biopharmaceuticals Inc	13.79	$ 356.573 Millions	$ 25.854 Millions
Q32 Bio Inc	13.67	$ 255.312 Millions	$ 18.682 Millions
Geron Corporation	13.48	$ 138.881 Millions	$ 10.305 Millions
Arrowhead Pharmaceuticals Inc	13.40	$ 258.704 Millions	$ 19.301 Millions
Ascendis Pharma A	13.39	$ 719.918 Millions	$ 53.749 Millions
Assembly Biosciences Inc	12.93	$ 156.937 Millions	$ 12.139 Millions
Trevi Therapeutics Inc	12.87	$ 63.534 Millions	$ 4.935 Millions
Mirati Therapeutics Inc	12.85	$ 454.212 Millions	$ 35.336 Millions
Savara Inc	12.82	$ 106.281 Millions	$ 8.291 Millions
Aprea Therapeutics Inc	12.81	$ 52.334 Millions	$ 4.085 Millions
Bio path Holdings inc	12.62	$ 15.382 Millions	$ 1.219 Millions
Cymabay Therapeutics Inc	12.59	$ 218.594 Millions	$ 17.358 Millions
Sage Therapeutics Inc	12.34	$ 1,122.250 Millions	$ 90.956 Millions
Prothena Corporation Public Limited Company	12.29	$ 390.304 Millions	$ 31.763 Millions
Guardion Health Sciences Inc	12.10	$ 5.555 Millions	$ 0.459 Millions

Date modified: 2026-09-08T15:09:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.